Here's Why Valeant Is Happy To Relinquish Its European Brodalumab Rights
Why Merck And Roche Should Be Worried About DelMar Pharmaceuticals Inc.
BioZone Pharmaceuticals: Dr. Frost's Next Big Thing
Why The Smart Money Points To Spherix
Two Very Good Reasons Why Blue Calypso Stock Looks Undervalued.
A Potentially Huge Market, And A Company That Might Be Well-Placed To Take Advantage Of It.
A Biotech With Hidden Value?